DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,385,478 | +9.8% | 404,617 | +6.2% | 0.54% | +12.1% |
| Q2 2023 | $91,439,040 | +4.0% | 380,996 | +9.2% | 0.48% | -0.4% |
| Q1 2023 | $87,919,365 | +0.9% | 348,831 | +6.3% | 0.48% | -2.2% |
| Q4 2022 | $87,092,265 | +29.2% | 328,130 | +25.7% | 0.49% | +20.0% |
| Q3 2022 | $67,420,000 | +2.5% | 261,024 | +0.6% | 0.41% | +9.4% |
| Q2 2022 | $65,800,000 | -2.5% | 259,544 | +12.8% | 0.37% | +16.5% |
| Q1 2022 | $67,481,000 | -3.0% | 230,052 | +8.8% | 0.32% | +2.6% |
| Q4 2021 | $69,560,000 | +14.9% | 211,422 | +6.3% | 0.31% | +7.9% |
| Q3 2021 | $60,559,000 | +13.7% | 198,919 | +0.2% | 0.29% | +10.3% |
| Q2 2021 | $53,256,000 | +19.6% | 198,448 | +0.3% | 0.26% | +8.7% |
| Q1 2021 | $44,526,000 | +1.8% | 197,825 | +0.5% | 0.24% | -6.2% |
| Q4 2020 | $43,727,000 | +4.7% | 196,844 | +1.5% | 0.26% | -5.5% |
| Q3 2020 | $41,772,000 | +20.5% | 193,990 | -1.0% | 0.27% | +7.1% |
| Q2 2020 | $34,655,000 | +187.8% | 195,980 | +125.3% | 0.26% | +129.7% |
| Q1 2020 | $12,041,000 | -8.2% | 86,995 | +1.8% | 0.11% | +4.7% |
| Q4 2019 | $13,119,000 | +15.9% | 85,480 | +9.1% | 0.11% | +1.9% |
| Q3 2019 | $11,318,000 | – | 78,365 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |